Terms: = Head and neck cancer AND CEP17 AND Treatment
4 results:
1. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract] [Full Text] [Related]
2. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
[TBL] [Abstract] [Full Text] [Related]
3. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
[TBL] [Abstract] [Full Text] [Related]
4. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.
Yoon HH; Shi Q; Sukov WR; Lewis MA; Sattler CA; Wiktor AE; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
J Clin Oncol; 2012 Nov; 30(32):3932-8. PubMed ID: 22987085
[TBL] [Abstract] [Full Text] [Related]
